The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death.

ABSTRACT:

Introduction

Septic shock is highly lethal and its incidence is increasing. Although TNF-α plays a key role in sepsis pathogenesis, past efforts to therapeutically inhibit it had limited success. However, there is continued interest in such therapies and there are now ongoing Phase II sepsis trials testing the effects of AZD9773, a TNF-directed polyclonal antibody fragment preparation. Experience with anti-inflammatory agents suggested that their efficacy may relate to sepsis-associated risk of death.

Areas covered

An overview of the biology of TNF and experimental data implicating TNF as a key mediator in sepsis pathogenesis; a review of the earlier clinical experience with anti-TNF therapies demonstrating that when examined across 12 trials, these agents had a highly consi

SUBMITTER: Qiu P 

PROVIDER: S-EPMC3523300 | biostudies-literature | 2011 Nov

REPOSITORIES: biostudies-literature